FDA green­lights Ot­su­ka sub­sidiary's bile duct can­cer drug

Ot­su­ka sub­sidiary Tai­ho On­col­o­gy nabbed an ac­cel­er­at­ed ap­proval on Fri­day for Lyt­go­bi (futiba­tinib), its new ki­nase in­hibitor to treat adults with a type of pre­vi­ous­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER